All In Biotech

Drug Trial Radar · NCT06876662

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Last checked: Nov 20, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

279

Planned (sponsor's estimate)

Start

May 20, 2025

Primary completion

May 2030

Study completion Dec 2032

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Mar 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.

Conditions

  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin Lymphoma

Interventions

  • PirtobrutinibDrug

    Administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with a Grade ≥3 treatment-emergent adverse events (TEAEs)Time frame: Time from the Date of the First Dose of Study Intervention (Study Day 1) through 30 Days (+ 7-day window) After the Date of the Last Dose of Study Intervention or The First Date Starting a New Anticancer Therapy, whichever is Earlier

Locations

36 sites in 8 countries. Site status is shown where the registry gives one.

  • Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • The Emory Clinic

    Atlanta, Georgia · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Mayo Clinic- Minnesota

    Rochester, Minnesota · Recruiting

  • University Of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Cayuga Cancer Center

    Ithaca, New York · Active not recruiting

  • Northwell Health

    Lake Success, New York · Recruiting

  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York

    New York, New York · Recruiting

  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York

    New York, New York · Active not recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • University of Pennsylvania Hospital

    Philadelphia, Pennsylvania · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Swedish Cancer Institute

    Seattle, Washington · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Flinders Medical Centre

    Adelaide, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Australia · Completed

  • Linear Clinical Research

    Victoria, Australia · Active not recruiting

  • CHU de Nantes - Hotel Dieu

    Nantes, France · Recruiting

  • IRCCS-AOU di Bologna-Policlinico S.Orsola-Malpighi

    Bologna, Italy · Completed

  • Ospedale San Raffaele

    Milan, Italy · Recruiting

  • Nagoya Medical Center

    Aichi-Ken, Japan · Active not recruiting

  • National Cancer Center Hospital

    Cho-ku, Japan · Completed

  • National Hospital Organization Kyushu Cancer Center

    Fukuoka, Japan · Active not recruiting

  • Tokai University Hospital- Isehara Campus

    Isehara, Japan · Active not recruiting

  • Tohoku University Hospital

    Miyagi-Ken, Japan · Active not recruiting

  • Hokkaido University Hospital

    Sapporo, Japan · Active not recruiting

  • Pratia MCM Krakow

    Krakow, Poland · Recruiting

  • Instytut Hermatologii I Transfuzjologii

    Warsaw, Poland · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • St James's University Hospital

    Leeds, United Kingdom · Recruiting

  • Churchill Hospital

    Oxford, United Kingdom · Recruiting

  • Derriford Hospital

    Plymouth, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.